Pinchbeck Lauren R, Hillier Andrew, Kowalski Joseph J, Kwochka Kenneth W
Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus 43210, USA.
J Am Vet Med Assoc. 2002 Jun 15;220(12):1807-12. doi: 10.2460/javma.2002.220.1807.
OBJECTIVE To compare clinical efficacy of pulse administration with itraconazole versus once daily administration for the treatment of cutaneous and otic M pachydermatis infection in dogs.
Randomized controlled trial.
20 dogs.
Dogs were treated with itraconazole orally (n = 10/group), using a pulse administration regimen (5 mg/kg [2.3 mg/lb], PO, q 24 h for 2 consecutive days per week for 3 weeks) or once daily administration (5 mg/kg, PO, q 24 h for 21 days). No other treatment was permitted. On days 0 and 21, clinical severity of cutaneous and otic disease was assessed, and samples were collected for cytologic examination and yeast culture. Cytology (sum of the mean number of yeast organisms per oil immersion field for affected sites) and culture (mean of the score for extent of yeast growth for samples from affected sites) scores were calculated.
For dogs in both treatment groups, clinical severity of cutaneous and otic disease was significantly decreased by day 21, but decrease in severity was not significantly different between groups. Similarly, skin cytology, skin culture, and ear culture scores were significantly decreased on day 21, compared with day 0, for both groups, but decreases were not significantly different between groups except that dogs in the pulse administration group had a significantly greater decrease in ear culture scores than did dogs in the daily administration group. However, when cytology scores only for ear samples were analyzed, day 21 score was not significantly decreased, compared with day 0 score, for either group.
Results suggested that both pulse administration and once daily administration of itraconazole were efficacious in the treatment of M pachydermatis cutaneous infection in dogs. However, adjunctive treatment may be needed in dogs with M pachydermatis otitis.
目的 比较伊曲康唑脉冲给药与每日一次给药治疗犬皮肤和耳部厚皮马拉色菌感染的临床疗效。
随机对照试验。
20只犬。
犬口服伊曲康唑（每组n = 10只），采用脉冲给药方案（5mg/kg[2.3mg/lb]，口服，每24小时一次，每周连续2天，共3周）或每日一次给药（5mg/kg，口服，每24小时一次，共21天）。不允许进行其他治疗。在第0天和第21天，评估皮肤和耳部疾病的临床严重程度，并采集样本进行细胞学检查和酵母菌培养。计算细胞学评分（感染部位每个油镜视野酵母菌数量的平均值总和）和培养评分（感染部位样本酵母菌生长程度评分的平均值）。
两个治疗组的犬在第21天时，皮肤和耳部疾病的临床严重程度均显著降低，但两组间严重程度的降低无显著差异。同样，与第0天相比，两组在第21天时皮肤细胞学、皮肤培养和耳部培养评分均显著降低，但除脉冲给药组犬的耳部培养评分下降幅度显著大于每日给药组犬外，两组间的下降幅度无显著差异。然而，仅分析耳部样本的细胞学评分时，两组在第21天的评分与第0天相比均未显著降低。
结果表明，伊曲康唑脉冲给药和每日一次给药对治疗犬皮肤厚皮马拉色菌感染均有效。然而，患有厚皮马拉色菌性中耳炎的犬可能需要辅助治疗。
